AbbVie Inc (ABBV)vsTrinity Biotech plc (TRIB)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
TRIB
Trinity Biotech plc
$0.60
0.00%
HEALTHCARE · Cap: $12.18M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 125821% more annual revenue ($61.16B vs $48.57M). ABBV leads profitability with a 6.9% profit margin vs -75.9%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
TRIB
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Margin of Safety
+85.1%
Fair Value
$5.52
Current Price
$0.60
$4.92 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
No standout strengths identified
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -1913.0% — below average capital efficiency
Revenue declined 5.5%
Earnings declined 77.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : TRIB
PEG of 1.30 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : TRIB
The primary concerns for TRIB are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while TRIB is a turnaround play — different risk/reward profiles.
TRIB carries more volatility with a beta of 0.79 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 27/100). TRIB offers better value entry with a 85.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Trinity Biotech plc
HEALTHCARE · MEDICAL DEVICES · USA
Trinity Biotech plc acquires, develops, manufactures and markets medical diagnostic products for the clinical laboratory and point of care (POC) segments of the diagnostic market in the United States, Africa, Asia and Europe. The company is headquartered in Bray, Ireland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?